ClinicalTrials.gg
CompletedNCT03151551SPIRIT-H2HUpdated Nov 3, 2020Results posted

A Study of Ixekizumab (LY2439821) Versus Adalimumab in Participants With Psoriatic Arthritis

A Phase 4 interventional study of Ixekizumab and Adalimumab in Psoriatic Arthritis, sponsored by Eli Lilly and Company. Completed at 131 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-03.

Sponsored by Eli Lilly and Company · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
566
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies in Arthritis, Psoriatic with a site in India — 1 open to participants now, 5 under way, 4 of them phase 3. Arthritis, Psoriatic · India.

Enrollment
4th of 13
566 · median 508
Started
2017
with 1 other
Phase 4
4 of 13
1 open now
Registered
3rd of 13
by date
Lead sponsor
2 of 13
Eli Lilly and Company

Among the 13 studies in Arthritis, Psoriatic with a site in India, this one is the 4th largest by enrollment, is one of 2 that started in 2017, is one of 4 in phase 4, and was the 3rd registered.

Arthritis, Psoriatic

601 studies on the registry are indexed under Arthritis, Psoriatic; 128 are open to participants now.

Browse Arthritis, Psoriatic studies →

Open to participants now

1 of the 13 studies in Arthritis, Psoriatic with a site in India is open now. Recruiting first, the newest first:

A study can be open while its sites in India have not opened yet or have stopped. Only those recruiting at a site in India →

Who these studies take

Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Arthritis, Psoriatic with a site in India, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effectiveness and safety of ixekizumab versus adalimumab in participants with psoriatic arthritis (PsA) who are biologic disease-modifying anti-rheumatic drugs (DMARD) naive.

03

Conditions studied

  • Psoriatic Arthritis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Presence of established diagnosis of active psoriatic arthritis for at least 6 months, and currently meets Classification for Psoriatic Arthritis (CASPAR) criteria
  • Active PsA defined as the presence of at least 3 (out of 68) tender and at least 3 (out of 66) swollen joints
  • Presence of active plaque psoriasis with a BSA ≥3%
  • Men must agree to use a reliable method of or remain abstinent during the study
  • Women must agree to use reliable birth control or remain abstinent during the study and for at least 12 weeks after stopping treatment
  • Have had an inadequate response when treated with 1 or more conventional synthetic disease-modifying antirheumatic drugs (csDMARDs)

Exclusion criteria

Exclusion Criteria:

  • Current or prior use of biologic agents for treatment of Ps or PsA
  • Evidence of active inflammatory arthritic syndromes or spondyloarthropathies other than PsA
  • Have participated in any study with interleukin 17 (IL-17) antagonists, including ixekizumab
  • Serious disorder or illness other than psoriatic arthritis
  • Serious infection within the last 3 months
  • Active Crohn's disease or active ulcerative colitis
  • Active vasculitis or uveitis
  • Diagnosis of or history of malignant disease \<5 years prior to randomization
  • Women who are breastfeeding
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
566 participants (actual)

Study arms

  • Experimental
    Ixekizumab

    160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline for all participants. 80 mg ixekizumab given once every 2 weeks (Q2W) SC from week 2 to week 12 and once every 4 weeks (Q4W) thereafter for participants with moderate-to-severe plaque Ps. 80 mg ixekizumab given SC Q4W starting week 4 for participants not meeting criteria for moderate-to-severe plaque Ps.

    Drug: Ixekizumab

  • Active comparator
    Adalimumab

    80 mg adalimumab given SC at baseline followed by 40 mg Q2W given SC starting week 1 for participants with moderate-to-severe plaque Ps. 40 mg adalimumab given Q2W SC at baseline followed by 40 mg Q2W starting at Week 2 given SC for participants not meeting criteria for moderate-to-severe plaque Ps.

    Drug: Adalimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)

    ACR50 response is a ≥50% improvement from baseline for tender joint count(TJC)\& swollen joint count (SJC)\& in at least 3 of the following 5 criteria: Participant's(pts) assessment of joint pain Visual Analog Scale (VAS),Pts Global Assessment of Disease Activity (PatGA)VAS, Physician's Global Assessment of Disease Activity (PGA)VAS, Pts assessment of physical function using the Health Assessment Questionnaire-Disability Index(HAQ-DI), or High Sensitivity(assay)C-Reactive Protein (hs-CRP). PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Pts achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Pts with active plaque PsO with a BSA≥3% \& PASI=0 at baseline were considered PASI100 responders if they had achieved PASI=0 \& BSA=0 at week 24.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants Achieving ACR50

    ACR50 response is defined as a ≥50% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of joint pain Visual Analog Scale (VAS), Participant's Global Assessment of Disease Activity (PatGA) VAS, Physician's Global Assessment of Disease Activity (PGA) VAS, participant's assessment of physical function using the Health Assessment Questionnaire-Disability Index (HAQ-DI), or High Sensitivity (assay) C-Reactive Protein (hs-CRP).

    Time frame: Week 24

  2. Percentage of Participants Achieving PASI100

    PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Participants achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Any participants with active plaque psoriasis (PsO) with a BSA ≥3% and PASI = 0 at baseline were considered PASI100 responders if \& only if they had achieved PASI=0 \& BSA=0 at week 24.

    Time frame: Week 24

Other outcomes

  1. Change From Baseline in Tender Joint Count (TJC)

    TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model that included treatment group, concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  2. Change From Baseline in Swollen Joint Count (SJC)

    SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM model that included treatment group, concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  3. Change From Baseline in Participant's Assessment of Pain Visual Analogue Score (VAS)

    The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  4. Change From Baseline in Participant's Global Assessment of Disease Activity

    The patient's overall assessment of his or her PsA activity was recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  5. Change From Baseline in Physician's Global Assessment of Disease Activity

    The investigator was asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  6. Change From Baseline in C-Reactive Protein (CRP)

    CRP is the ACR Core Set laboratory measure of acute-phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on the participant's PsA. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  7. Change From Baseline in HAQ-DI

    HAQ-DI is a participant reported questionnaire that measures disease-associated disability (physical function). It consists of 24 questions with 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other daily activities. The disability section scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do), covering the 8 domains. The reported use of special aids or devices and/or the need for assistance of another person to perform these activities is assessed. The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  8. Percentage of Participants Simultaneously Achieving ACR50 and PASI100

    ACR50 response is a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of VAS, Pts Global Assessment of Disease Activity (PatGA) VAS, Physician's Global Assessment of Disease Activity (PGA)VAS, participant assessment of physical function using the HAQ-DI, or High Sensitivity(assay) C-Reactive Protein (hs-CRP). PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Participant achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Pts achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Pts with active plaque PsO with a BSA≥3% \& PASI=0 at baseline were considered PASI100 responders if they had achieved PASI=0 \& BSA=0 at week 52.

    Time frame: Week 52

  9. Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)

    The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in milligrams per liter), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  10. Percentage of Participants Achieving Minimal Disease Activity (MDA)

    MDA is a composite of 7 key outcome measures: TJC ≤1; SJC ≤1; psoriasis activity and severity index (PASI total score) ≤1 or BSA ≤3; participant pain VAS score of ≤15; participant global disease activity VAS score of ≤20; HAQ-DI score ≤0.5; and tender entheseal points ≤1. Participants are classified as achieving MDA if they fulfill 5 of 7 outcome measures.

    Time frame: Week 52

  11. Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)

    The PsARC is a composite criteria reported in terms of the percentage of participants achieving response according to the following criterion: TJC, SJC, PGA, and PatGA. Overall response is defined by improvement from baseline assessment in 2 of 4 criteria, 1 of which must be a joint count; there must not be worsening in any of the 4 criteria: at least 30% reduction in TJC, at least 30% reduction in SJC, at least a 20 millimeter (mm) reduction in PGA and at least a 20 mm reduction in PatGA.

    Time frame: Week 52

  12. Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score

    The CPDAI is a validated instrument intended to assess composite psoriatic disease activity and response to therapy. Domains include peripheral arthritis as assessed by the number of tender and swollen joints and the HAQ-DI, skin as assessed by the PASI and the Dermatology Life Quality Index (DLQI), enthesitis as assessed by the number of sites with enthesitis and the HAQ-DI, and dactylitis as assessed by the number of digits affected. Each domain with the exception of spinal disease is scored from 0-3. Individual domain scores are summed to give an overall composite score (range 0-12) with a higher score indicating higher disease activity. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  13. Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index in Participants With Enthesitis at Baseline

    The SPARCC enthesitis index evaluates tenderness in a total of 16 entheseal sites: the greater trochanter (right/left \[R/L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial epicondyles of humerus (R/L),Lateral epicondyle humerus (R/L) and the supraspinatus insertion (R/L). Tenderness at each site is quantified on a dichotomous basis: 0 = nontender and 1 = tender. The results from each site are then added to produce a total score (range 0 to 16) with the Higher scores indicating more severe enthesitis. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  14. Change From Baseline in the Leeds Enthesitis Index (LEI) in Participants With Enthesitis at Baseline

    The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle,(R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  15. Change From Baseline in the Leeds Dactylitis Index-Basic (LDI-B) in Participants With Dactylitis at Baseline

    The LDI-B measures the severity of dactylitis.In each digit,the ratio of the circumference(cf) of the affected digit to the cf of the digit on the opposite hand or foot measured in mm. Each dactylitic digit is defined by a minimum increase of 10% in cf over the contra-lateral digit.If the same digits on each hand or foot were thought to be involved,the clinician referred to a table of normative values for a value which was used to provide the comparison.If the ratio is \>1.1,then subtract 1 from the calculated ratio and multiply it by 100 and the tenderness score of 0(not tender) or 1(tender).Otherwise,if the ratio of the cf of the digit is ≤1.1,then the LDI-B score is set to 0.LDI-B score can be \>=0 with higher numbers indicating worse dactylitis.LS mean was calculated using MMRM model: treatment group,concomitant csDMARD use at baseline,moderate-to-severe Ps involvement,visit as fixed factors,baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  16. Change From Baseline in Psoriasis Body Surface Area (BSA)

    The investigator evaluates the percentage involvement of psoriasis on each participant's BSA on a continuous scale from 0% = no involvement to 100% = full involvement, where 1% corresponded to the size of the participant's handprint including the palm, fingers, and thumb. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  17. Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Fingernails Score in the Subgroup of Participants With Fingernail Involvement at Baseline

    The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis). LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  18. Change From Baseline in the Itch NRS

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis is indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  19. Change From Baseline in Fatigue Severity NRS (Fatigue NRS) Score

    The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rate their fatigue (weariness, tiredness) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  20. Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36): Physical Component Summary (PCS)

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  21. Change From Baseline in SF-36: Mental Component Summary (MCS)

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  22. Change From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) United Kingdom(UK) Population-Based Index Score

    The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The descriptive part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.The EQ-5D-5L health states were converted into a single summary index by applying a crosswalk using a UK Population value set to each of the levels in each dimension.This produced participant-level index scores between -0.594 and 1.0 (worse to better health). LS mean was calculated using MMRM model that included treatment group,concomitant csDMARD use at baseline,moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  23. Change From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) VAS Score

    EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (worst health you can imagine) to 100mm VAS (best health you can imagine). LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  24. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Scores range from 0 to 30 (less to more impairment), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

    Time frame: Baseline, Week 52

  25. Percentage of Participants Answering "Mostly Satisfied" to Each Question in Treatment Satisfaction Questionnaire (TSQ)

    The TSQ is a clinician-administered questionnaire that provides an assessment of the patient's opinion of the effectiveness, safety, and overall satisfaction of the study medication. Participants were asked to respond to questionnaire items using a 4-point Likert scale (from "mostly satisfied" to "mostly dissatisfied").

    Time frame: Week 52

  26. Number of Participants Who Answered "Yes" to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS)

    The C-SSRS is a scale that captures the occurrence, severity, and frequency of suicide-related ideations and behaviors during the assessment period. 1. Wish to be dead 2. Non-specific active suicidal thoughts 3. Active suicidal ideation with any methods (not plan) without intent to act 4. Active suicidal ideation with some intent to act, without specific plan 5. Active suicidal ideation with specific plan and intent 6. Preparatory acts or behavior 7. Aborted attempt 8. Interrupted attempt 9. Non-fatal suicide attempt 10. Completed suicide

    Time frame: Week 52

07

Results

Posted Apr 2, 2019

Participant flow

Per protocol and statistical analysis plan (SAP), the primary and secondary analysis were performed to compare all ixekizumab participants together versus all adalimumab participants together.

Open-Label Treatment Period
Participant flow — Open-Label Treatment Period
MilestoneIxekizumabAdalimumab
Started283283
Received at least one dose of study drug283283
Ixe 160 mg at baseline, 80 mg q2w/q4w490
Ixe 160 mg at baseline, 80 mg q4w2180
Ada 80 mg at baseline, 40 mg q2w051
Ada 40 mg at baseline, 40 mg q2w0219
Completed265259
Not completed1824
Withdrew: Adverse event02
Withdrew: Lost to follow-up11
Withdrew: Withdrawal by subject1218
Withdrew: Lack of efficacy11
Withdrew: Physician decision30
Withdrew: Protocol deviation12
Post-Treatment Follow-Up Period
Participant flow — Post-Treatment Follow-Up Period
MilestoneIxekizumabAdalimumab
Started265258
Completed240230
Not completed2528
Withdrew: Adverse event13
Withdrew: Lost to follow-up42
Withdrew: Withdrawal by subject2022
Withdrew: Physician decision01

Outcome measures

PrimaryPercentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)

ACR50 response is a ≥50% improvement from baseline for tender joint count(TJC)\& swollen joint count (SJC)\& in at least 3 of the following 5 criteria: Participant's(pts) assessment of joint pain Visual Analog Scale (VAS),Pts Global Assessment of Disease Activity (PatGA)VAS, Physician's Global Assessment of Disease Activity (PGA)VAS, Pts assessment of physical function using the Health Assessment Questionnaire-Disability Index(HAQ-DI), or High Sensitivity(assay)C-Reactive Protein (hs-CRP). PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Pts achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Pts with active plaque PsO with a BSA≥3% \& PASI=0 at baseline were considered PASI100 responders if they had achieved PASI=0 \& BSA=0 at week 24.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)
percentage of participantsIxekizumabAdalimumab
Percentage of Participants Simultaneously Achieving American College of Rheumatology 50 (ACR50) and Psoriasis Area and Severity Index 100 (PASI100)36 (30.4 to 41.6)27.9 (22.7 to 33.1)
Statistical analysis
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.036 · Rate difference: 8.1 · 95% CI 0.5 to 15.8
SecondaryPercentage of Participants Achieving ACR50

ACR50 response is defined as a ≥50% improvement from baseline for tender joint count (TJC) and swollen joint count (SJC) and in at least 3 of the following 5 criteria: Participant's assessment of joint pain Visual Analog Scale (VAS), Participant's Global Assessment of Disease Activity (PatGA) VAS, Physician's Global Assessment of Disease Activity (PGA) VAS, participant's assessment of physical function using the Health Assessment Questionnaire-Disability Index (HAQ-DI), or High Sensitivity (assay) C-Reactive Protein (hs-CRP).

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving ACR50
percentage of participantsIxekizumabAdalimumab
Percentage of Participants Achieving ACR5050.5 (44.7 to 56.4)46.6 (40.8 to 52.5)
Statistical analysis
  • Ixekizumab vs Adalimumab · Rate difference: 3.9 · 95% CI -4.3 to 12.1
SecondaryPercentage of Participants Achieving PASI100

PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Participants achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Any participants with active plaque psoriasis (PsO) with a BSA ≥3% and PASI = 0 at baseline were considered PASI100 responders if \& only if they had achieved PASI=0 \& BSA=0 at week 24.

Time frame:
Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving PASI100
percentage of participantsIxekizumabAdalimumab
Percentage of Participants Achieving PASI10060.1 (54.4 to 65.8)46.6 (40.8 to 52.5)
Statistical analysis
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.001 · Rate difference: 13.4 · 95% CI 5.3 to 21.6
Other pre-specifiedChange From Baseline in Tender Joint Count (TJC)

TJC is the number of tender and painful joints determined for each participant by examination of 68 joints. Joints were assessed by pressure and joint manipulation on physical examination. Participants were asked for pain sensations on these manipulations and watched for spontaneous pain reactions. Any positive response on pressure, movement, or both was translated into a single tender-versus-nontender dichotomy. Least Square(LS) Mean was calculated using Mixed Model Repeated Measures (MMRM) model that included treatment group, concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Tender Joint Count (TJC)
score on a scaleIxekizumabAdalimumab
Change From Baseline in Tender Joint Count (TJC)-15.91 ± 0.566-14.88 ± 0.569
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.155 · Mean difference (final values): -1.03 · 95% CI -2.46 to 0.39
Other pre-specifiedChange From Baseline in Swollen Joint Count (SJC)

SJC is the number of swollen joints determined for each participant by examination of 66 joints. Joints were classified as either swollen or not swollen. Swelling was defined as palpable fluctuating synovitis of the joint. LS mean was calculated using MMRM model that included treatment group, concomitant conventional synthetic disease-modifying anti-rheumatic drugs (csDMARD) use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Swollen Joint Count (SJC)
score on a scaleIxekizumabAdalimumab
Change From Baseline in Swollen Joint Count (SJC)-9.58 ± 0.196-9.53 ± 0.198
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.823 · Mean difference (final values): -0.06 · 95% CI -0.54 to 0.43
Other pre-specifiedChange From Baseline in Participant's Assessment of Pain Visual Analogue Score (VAS)

The pain VAS is a participant-administered single-item scale designed to measure current joint pain from Psoriatic arthritis (PsA) using a 100-millimeter(mm) horizontal VAS. Overall severity of participant's joint pain from PsA is indicated by marking a vertical tick on the horizontal 100-mm scale, where the left end from 0 mm (no pain) to right end 100 mm (worst possible joint pain). LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimeters (mm)
Change From Baseline in Participant's Assessment of Pain Visual Analogue Score (VAS)
millimeters (mm)IxekizumabAdalimumab
Change From Baseline in Participant's Assessment of Pain Visual Analogue Score (VAS)-37.21 ± 1.623-36.54 ± 1.621
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.752 · Mean difference (final values): -0.67 · 95% CI -4.80 to 3.47
Other pre-specifiedChange From Baseline in Participant's Global Assessment of Disease Activity

The patient's overall assessment of his or her PsA activity was recorded using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline in Participant's Global Assessment of Disease Activity
Millimeter (mm)IxekizumabAdalimumab
Change From Baseline in Participant's Global Assessment of Disease Activity-40.61 ± 1.594-37.82 ± 1.596
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.177 · Mean difference (final values): -2.79 · 95% CI -6.83 to 1.26
Other pre-specifiedChange From Baseline in Physician's Global Assessment of Disease Activity

The investigator was asked to give an overall assessment of the severity of the participant's current PsA activity using a 100-mm horizontal VAS, where 0 represents no disease activity and 100 represents extremely active disease. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Millimeter (mm)
Change From Baseline in Physician's Global Assessment of Disease Activity
Millimeter (mm)IxekizumabAdalimumab
Change From Baseline in Physician's Global Assessment of Disease Activity-48.15 ± 1.113-46.79 ± 1.097
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.332 · Mean difference (final values): -1.35 · 95% CI -4.08 to 1.38
Other pre-specifiedChange From Baseline in C-Reactive Protein (CRP)

CRP is the ACR Core Set laboratory measure of acute-phase reactant. It was measured with a high sensitivity assay at the central laboratory to help assess the effect of ixekizumab on the participant's PsA. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · Milligram per Liter (mg/L)
Change From Baseline in C-Reactive Protein (CRP)
Milligram per Liter (mg/L)IxekizumabAdalimumab
Change From Baseline in C-Reactive Protein (CRP)-5.68 ± 0.462-6.01 ± 0.461
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.592 · Mean difference (final values): 0.32 · 95% CI -0.86 to 1.50
Other pre-specifiedChange From Baseline in HAQ-DI

HAQ-DI is a participant reported questionnaire that measures disease-associated disability (physical function). It consists of 24 questions with 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and other daily activities. The disability section scores the participant's self-perception on the degree of difficulty (0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, and 3 = unable to do), covering the 8 domains. The reported use of special aids or devices and/or the need for assistance of another person to perform these activities is assessed. The HAQ-DI is a composite ranging from 0-3 with lower scores indicating less functional disability. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in HAQ-DI
score on a scaleIxekizumabAdalimumab
Change From Baseline in HAQ-DI-0.68 ± 0.035-0.62 ± 0.035
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.176 · Mean difference (final values): -0.06 · 95% CI -0.15 to 0.03
Other pre-specifiedPercentage of Participants Simultaneously Achieving ACR50 and PASI100

ACR50 response is a ≥50% improvement from baseline for TJC and SJC and in at least 3 of the following 5 criteria: Participant's assessment of VAS, Pts Global Assessment of Disease Activity (PatGA) VAS, Physician's Global Assessment of Disease Activity (PGA)VAS, participant assessment of physical function using the HAQ-DI, or High Sensitivity(assay) C-Reactive Protein (hs-CRP). PASI is an index combining assessments of the extent of body-surface involvement in head, trunk, arms, legs, and severity of desquamation, erythema and plaque thickness in each region, yielding overall score of 0-no involvement, to 72-most severe involvement. Participant achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Pts achieving PASI100 were defined as having 100% improvement in the PASI score compared to baseline. Pts with active plaque PsO with a BSA≥3% \& PASI=0 at baseline were considered PASI100 responders if they had achieved PASI=0 \& BSA=0 at week 52.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Simultaneously Achieving ACR50 and PASI100
percentage of participantsIxekizumabAdalimumab
Percentage of Participants Simultaneously Achieving ACR50 and PASI10039.2 (33.5 to 44.9)26.1 (21.0 to 31.3)
Statistical analysis
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = <0.001 · Rate difference: 13.1 · 95% CI 5.4 to 20.7
Other pre-specifiedChange From Baseline in Disease Activity Score-CRP (DAS28-CRP)

The DAS28-CRP is a measure of disease activity in 28 joints that consists of a composite numerical score with the following variables: TJC28, SJC28, hs-CRP (measured in milligrams per liter), and Participant's Global Assessment of Disease Activity recorded by participants on a 0 to 100 VAS. For DAS28-CRP, the Tender Joint Count 28 (TJC28) and Swollen Joint Count (SJC28) are a subset of TJC and SJC, and include 14 joints on each side of the body: 2 shoulders, 2 elbows, 2 wrists, 10 metacarpophalangeal joints, the 2 interphalangeal joints of the thumb, the 8 proximal interphalangeal joints, and the 2 knees. DAS28 values range from 0 to 9.4. Higher values indicate more severe symptoms and greater functional impairment. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)
score on a scaleIxekizumabAdalimumab
Change From Baseline in Disease Activity Score-CRP (DAS28-CRP)-2.45 ± 0.071-2.36 ± 0.071
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.368 · Mean difference (final values): -0.08 · 95% CI -0.26 to 0.10
Other pre-specifiedPercentage of Participants Achieving Minimal Disease Activity (MDA)

MDA is a composite of 7 key outcome measures: TJC ≤1; SJC ≤1; psoriasis activity and severity index (PASI total score) ≤1 or BSA ≤3; participant pain VAS score of ≤15; participant global disease activity VAS score of ≤20; HAQ-DI score ≤0.5; and tender entheseal points ≤1. Participants are classified as achieving MDA if they fulfill 5 of 7 outcome measures.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Minimal Disease Activity (MDA)
percentage of participantsIxekizumabAdalimumab
MDA-6 Entheseal Points48.1 (42.2 to 53.9)42.8 (37.0 to 48.5)
MDA-18 Entheseal Points47.3 (41.5 to 53.2)41.0 (35.3 to 46.7)
Statistical analysis
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.108 · Rate difference: 6.4 · 95% CI -1.8 to 14.5
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.179 · Rate difference: 5.3 · 95% CI -2.9 to 13.5
Other pre-specifiedPercentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)

The PsARC is a composite criteria reported in terms of the percentage of participants achieving response according to the following criterion: TJC, SJC, PGA, and PatGA. Overall response is defined by improvement from baseline assessment in 2 of 4 criteria, 1 of which must be a joint count; there must not be worsening in any of the 4 criteria: at least 30% reduction in TJC, at least 30% reduction in SJC, at least a 20 millimeter (mm) reduction in PGA and at least a 20 mm reduction in PatGA.

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)
percentage of participantsIxekizumabAdalimumab
Percentage of Participants Achieving Psoriatic Arthritis Response Criteria (PsARC)66.8 (61.3 to 72.3)65.7 (60.2 to 71.3)
Statistical analysis
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.846 · Rate difference: -1.1 · 95% CI -8.9 to 6.7
Other pre-specifiedChange From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score

The CPDAI is a validated instrument intended to assess composite psoriatic disease activity and response to therapy. Domains include peripheral arthritis as assessed by the number of tender and swollen joints and the HAQ-DI, skin as assessed by the PASI and the Dermatology Life Quality Index (DLQI), enthesitis as assessed by the number of sites with enthesitis and the HAQ-DI, and dactylitis as assessed by the number of digits affected. Each domain with the exception of spinal disease is scored from 0-3. Individual domain scores are summed to give an overall composite score (range 0-12) with a higher score indicating higher disease activity. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score
score on a scaleIxekizumabAdalimumab
Change From Baseline in Modified Composite Psoriatic Disease Activity Index (mCPDAI) Score-4.35 ± 0.136-3.85 ± 0.136
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.004 · Mean difference (final values): -0.49 · 95% CI -0.83 to -0.16
Other pre-specifiedChange From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index in Participants With Enthesitis at Baseline

The SPARCC enthesitis index evaluates tenderness in a total of 16 entheseal sites: the greater trochanter (right/left \[R/L\]), quadriceps tendon insertion into the patella (R/L), patellar ligament insertion into the patella and tibial tuberosity (R/L), Achilles tendon insertion (R/L), plantar fascia insertion (R/L), medial epicondyles of humerus (R/L),Lateral epicondyle humerus (R/L) and the supraspinatus insertion (R/L). Tenderness at each site is quantified on a dichotomous basis: 0 = nontender and 1 = tender. The results from each site are then added to produce a total score (range 0 to 16) with the Higher scores indicating more severe enthesitis. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index in Participants With Enthesitis at Baseline
score on a scaleIxekizumabAdalimumab
Change From Baseline in the Spondyloarthritis Research Consortium of Canada (SPARCC) Enthesitis Index in Participants With Enthesitis at Baseline-3.93 ± 0.234-4.06 ± 0.241
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.687 · Mean difference (final values): 0.12 · 95% CI -0.48 to 0.72
Other pre-specifiedChange From Baseline in the Leeds Enthesitis Index (LEI) in Participants With Enthesitis at Baseline

The LEI was developed specifically for use in PsA. It measures enthesitis at 6 sites (lateral epicondyle of humerus, right/left (R/L); medial femoral condyle,(R/L); Achilles tendon insertion, (R/L)). Each site is assigned a score of 0 (absent) or 1 (present); the results from each site are then added to produce a total score (range 0 to 6) with the higher scores indicating more severe enthesitis. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Leeds Enthesitis Index (LEI) in Participants With Enthesitis at Baseline
score on a scaleIxekizumabAdalimumab
Change From Baseline in the Leeds Enthesitis Index (LEI) in Participants With Enthesitis at Baseline-1.93 ± 0.113-2.02 ± 0.116
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.507 · Mean difference (final values): 0.10 · 95% CI -0.19 to 0.38
Other pre-specifiedChange From Baseline in the Leeds Dactylitis Index-Basic (LDI-B) in Participants With Dactylitis at Baseline

The LDI-B measures the severity of dactylitis.In each digit,the ratio of the circumference(cf) of the affected digit to the cf of the digit on the opposite hand or foot measured in mm. Each dactylitic digit is defined by a minimum increase of 10% in cf over the contra-lateral digit.If the same digits on each hand or foot were thought to be involved,the clinician referred to a table of normative values for a value which was used to provide the comparison.If the ratio is \>1.1,then subtract 1 from the calculated ratio and multiply it by 100 and the tenderness score of 0(not tender) or 1(tender).Otherwise,if the ratio of the cf of the digit is ≤1.1,then the LDI-B score is set to 0.LDI-B score can be \>=0 with higher numbers indicating worse dactylitis.LS mean was calculated using MMRM model: treatment group,concomitant csDMARD use at baseline,moderate-to-severe Ps involvement,visit as fixed factors,baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Leeds Dactylitis Index-Basic (LDI-B) in Participants With Dactylitis at Baseline
score on a scaleIxekizumabAdalimumab
Change From Baseline in the Leeds Dactylitis Index-Basic (LDI-B) in Participants With Dactylitis at Baseline-52.28 ± 11.495-48.89 ± 9.855
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.820 · Mean difference (final values): -3.40 · 95% CI -32.78 to 25.99
Other pre-specifiedChange From Baseline in Psoriasis Body Surface Area (BSA)

The investigator evaluates the percentage involvement of psoriasis on each participant's BSA on a continuous scale from 0% = no involvement to 100% = full involvement, where 1% corresponded to the size of the participant's handprint including the palm, fingers, and thumb. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Body Surface Area (BSA)
units on a scaleIxekizumabAdalimumab
Change From Baseline in Psoriasis Body Surface Area (BSA)-12.33 ± 0.623-10.79 ± 0.613
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.052 · Mean difference (final values): -1.54 · 95% CI -3.09 to 0.02
Other pre-specifiedChange From Baseline in the Nail Psoriasis Severity Index (NAPSI) Fingernails Score in the Subgroup of Participants With Fingernail Involvement at Baseline

The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed Ps 0 (none) to 4 (Ps in 4 quadrants of the fingernail) and fingernail matrix Ps 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix Ps in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis). LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Fingernails Score in the Subgroup of Participants With Fingernail Involvement at Baseline
score on a scaleIxekizumabAdalimumab
Change From Baseline in the Nail Psoriasis Severity Index (NAPSI) Fingernails Score in the Subgroup of Participants With Fingernail Involvement at Baseline-17.78 ± 0.731-15.08 ± 0.742
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.005 · Mean difference (final values): -2.70 · 95% CI -4.57 to -0.84
Other pre-specifiedChange From Baseline in the Itch NRS

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable." Overall severity of a participant's itching from psoriasis is indicated by circling the number that best described the worst level of itching in the past 24 hours. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in the Itch NRS
score on a scaleIxekizumabAdalimumab
Change From Baseline in the Itch NRS-3.83 ± 0.159-3.54 ± 0.159
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.158 · Mean difference (final values): -0.29 · 95% CI -0.68 to 0.11
Other pre-specifiedChange From Baseline in Fatigue Severity NRS (Fatigue NRS) Score

The Fatigue Severity NRS is a participant-administered single-item 11-point horizontal scale anchored at 0 and 10, with 0 representing "no fatigue" and 10 representing "as bad as you can imagine." Participants rate their fatigue (weariness, tiredness) by circling the 1 number that described their worst level of fatigue during the past 24 hours. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Fatigue Severity NRS (Fatigue NRS) Score
score on a scaleIxekizumabAdalimumab
Change From Baseline in Fatigue Severity NRS (Fatigue NRS) Score-3.03 ± 0.161-2.95 ± 0.161
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.711 · Mean difference (final values): -0.08 · 95% CI -0.49 to 0.33
Other pre-specifiedChange From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36): Physical Component Summary (PCS)

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36): Physical Component Summary (PCS)
score on a scaleIxekizumabAdalimumab
Change From Baseline in Medical Outcomes Study 36-item Short Form Health Survey (SF-36): Physical Component Summary (PCS)10.07 ± 0.5269.55 ± 0.524
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.439 · Mean difference (final values): 0.52 · 95% CI -0.80 to 1.85
Other pre-specifiedChange From Baseline in SF-36: Mental Component Summary (MCS)

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in SF-36: Mental Component Summary (MCS)
score on a scaleIxekizumabAdalimumab
Change From Baseline in SF-36: Mental Component Summary (MCS)5.23 ± 0.6604.77 ± 0.656
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.594 · Mean difference (final values): 0.46 · 95% CI -1.23 to 2.15
Other pre-specifiedChange From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) United Kingdom(UK) Population-Based Index Score

The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, and extreme problems. The descriptive part is comprised of the following 5 participant-reported dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression.The EQ-5D-5L health states were converted into a single summary index by applying a crosswalk using a UK Population value set to each of the levels in each dimension.This produced participant-level index scores between -0.594 and 1.0 (worse to better health). LS mean was calculated using MMRM model that included treatment group,concomitant csDMARD use at baseline,moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) United Kingdom(UK) Population-Based Index Score
score on a scaleIxekizumabAdalimumab
Change From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) United Kingdom(UK) Population-Based Index Score0.21 ± 0.0130.21 ± 0.013
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.979 · Mean difference (final values): -0.00 · 95% CI -0.03 to 0.03
Other pre-specifiedChange From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) VAS Score

EQ-5D-5L is a standardized measure of health status used to provide a simple, generic measure of health for clinical and economic appraisal. The EQ-5D-5L consists of 2 components: a descriptive system of the respondent's health and a rating of his/her current health state using a 0 (worst health you can imagine) to 100mm VAS (best health you can imagine). LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · millimeters (mm)
Change From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) VAS Score
millimeters (mm)IxekizumabAdalimumab
Change From Baseline in Measures of Health Utility (EuroQol-5 Dimensions 5 Level [EQ-5D 5L]) VAS Score22.26 ± 1.3717.48 ± 1.36
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = 0.008 · Mean difference (final values): 4.78 · 95% CI 1.28 to 8.28
Other pre-specifiedChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. The recall period of this scale is over the last "week." Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Scores range from 0 to 30 (less to more impairment), and a 4-point change from baseline is considered as the minimal clinically important difference threshold. LS mean was calculated using MMRM model that included treatment group, concomitant csDMARD use at baseline, moderate-to-severe plaque psoriasis involvement, visit as fixed factors, baseline value as covariate and baseline-by-visit and treatment-by-visit interactions terms.

Time frame:
Baseline, Week 52
Reported as:
Least squares mean · score on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
score on a scaleIxekizumabAdalimumab
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score-8.03 ± 0.273-6.91 ± 0.272
Statistical analysis
  • Ixekizumab vs Adalimumab · Mixed Models Analysis · p = <0.001 · Mean difference (final values): -1.12 · 95% CI -1.78 to -0.46
Other pre-specifiedPercentage of Participants Answering "Mostly Satisfied" to Each Question in Treatment Satisfaction Questionnaire (TSQ)

The TSQ is a clinician-administered questionnaire that provides an assessment of the patient's opinion of the effectiveness, safety, and overall satisfaction of the study medication. Participants were asked to respond to questionnaire items using a 4-point Likert scale (from "mostly satisfied" to "mostly dissatisfied").

Time frame:
Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Answering "Mostly Satisfied" to Each Question in Treatment Satisfaction Questionnaire (TSQ)
percentage of participantsIxekizumabAdalimumab
Effectiveness of Medication64.3 (58.7 to 69.9)58.7 (52.9 to 64.4)
Effectiveness over Time of Medication62.9 (57.3 to 68.5)56.2 (50.4 to 62.0)
Long Term Safety of Medication63.3 (57.6 to 68.9)58.7 (52.9 to 64.4)
Overall Satisfaction with Medication64.0 (58.4 to 69.6)59.0 (53.3 to 64.7)
Mostly Satisfied to any Questions70.0 (64.6 to 75.3)67.8 (62.4 to 73.3)
Statistical analysis
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.165 · Rate difference: 5.7 · 95% CI -2.4 to 13.7
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.098 · Rate difference: 6.7 · 95% CI -1.4 to 14.8
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.241 · Rate difference: 4.6 · 95% CI -3.4 to 12.6
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.215 · Rate difference: 4.9 · 95% CI -3.1 to 13.0
  • Ixekizumab vs Adalimumab · Regression, Logistic · p = 0.561 · Rate difference: 2.1 · 95% CI -5.5 to 9.7
Other pre-specifiedNumber of Participants Who Answered "Yes" to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS)

The C-SSRS is a scale that captures the occurrence, severity, and frequency of suicide-related ideations and behaviors during the assessment period. 1. Wish to be dead 2. Non-specific active suicidal thoughts 3. Active suicidal ideation with any methods (not plan) without intent to act 4. Active suicidal ideation with some intent to act, without specific plan 5. Active suicidal ideation with specific plan and intent 6. Preparatory acts or behavior 7. Aborted attempt 8. Interrupted attempt 9. Non-fatal suicide attempt 10. Completed suicide

Time frame:
Week 52
Reported as:
Count of participants · Participants
Number of Participants Who Answered "Yes" to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsIxekizumabAdalimumab
Number of Participants Who Answered "Yes" to Any 10 Questions in Columbia Suicide Severity Rating Scale (C-SSRS)97

Adverse events

Collected over Up To Week 52. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ixekizumab0/283 (0%)12/283 (4.2%)65/283 (23%)
Adalimumab0/283 (0%)35/283 (12.4%)44/283 (15.5%)
Ixekizumab Follow-up0/265 (0%)7/265 (2.6%)8/265 (3%)
Adalimumab Follow-up0/260 (0%)4/260 (1.5%)5/260 (1.9%)
Most frequent serious events
Showing 10 of 64
Most frequent serious events
EventIxekizumabAdalimumabIxekizumab Follow-upAdalimumab Follow-up
MenometrorrhagiaReproductive system and breast disorders1/1210/1330/1110/123
Maternal exposure during pregnancyInjury, poisoning and procedural complications0/1211/1330/1110/123
PyrexiaGeneral disorders2/2831/2830/2650/260
FallInjury, poisoning and procedural complications0/2832/2830/2650/260
ProstatitisReproductive system and breast disorders0/1621/1500/1540/137
AnaemiaBlood and lymphatic system disorders0/2830/2830/2651/260
Atrial fibrillationCardiac disorders1/2831/2830/2651/260
AstheniaGeneral disorders0/2830/2830/2651/260
Viral infectionInfections and infestations0/2830/2830/2651/260
SeizureNervous system disorders0/2830/2830/2651/260
Most frequent other events
Most frequent other events
EventIxekizumabAdalimumabIxekizumab Follow-upAdalimumab Follow-up
NasopharyngitisInfections and infestations38/28323/2835/2653/260
Upper respiratory tract infectionInfections and infestations18/28318/2833/2652/260
Injection site reactionGeneral disorders16/2834/2830/2650/260

Baseline characteristics

All randomized participants. Per protocol and statistical analysis plan, the primary and secondary analysis were performed to compare all ixekizumab participants together versus all adalimumab participants together.

Age, Continuous
Age, Continuous(years)IxekizumabAdalimumabTotal
Median47.5 ± 12.0248.3 ± 12.3047.9 ± 12.15
Sex: Female, Male
Sex: Female, Male(Participants)IxekizumabAdalimumabTotal
Female121133254
Male162150312
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IxekizumabAdalimumabTotal
Hispanic or Latino6365128
Not Hispanic or Latino198194392
Unknown or Not Reported222446
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IxekizumabAdalimumabTotal
American Indian or Alaska Native272754
Asian293362
Native Hawaiian or Other Pacific Islander000
Black or African American011
White222211433
More than one race51116
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)IxekizumabAdalimumabTotal
Argentina312758
Hungary151833
Ukraine151126
United Kingdom13720
Switzerland134
India202646
Spain241842
Canada5510
Sweden336
Austria448
Netherlands213
Belgium6511
Finland5611
Poland242953
Denmark134
Mexico323365
South Africa152136
Italy142539
Israel141428
Australia12517
France9312
Germany181634
08

Study locations

131 sites
  • Atencion Integral en Reumatología
    Ciudad Autonoma de Buenos Aire, Buenos Aires C1426AAL, Argentina
  • Clinica Adventista de Belgrano
    Ciudad de Buenos Aires, Buenos Aires C1430EGF, Argentina
  • CER Instituto Medico
    Quilmes, Buenos Aires B1878DVC, Argentina
  • Instituto de Asist Reumatologica Integral
    San Fernando, Buenos Aires B1646DBM, Argentina
  • Centro Medico Privado de Reumatologia
    San Miguel de Tucuman, Tucuman T4000AXL, Argentina
  • Organizacion Medica de Investigacion - OMI
    Ciudad Autonoma de Buenos Aire, C1015ABO, Argentina
  • Instituto Centenario
    Ciudad Autonoma de Buenos Aire, C1204AAD, Argentina
  • Hospital Ramos Mejia
    Ciudad Autonoma de Buenos Aire, C1221ADC, Argentina
  • Centro de Medicina Familiar Mindout Research
    Ciudad Autonoma de Buenos Aire, C1417EYG, Argentina
  • CENUDIAB
    Ciudad Autonoma de Buenos Aire, C1440AAD, Argentina
  • Consultora Integral de Salud S.R.L.
    Cordoba, 5004, Argentina
  • Centro Polivalente de Asistencia e Inv. Clinica CER-San Juan
    San Juan, J5402DIL, Argentina
  • Combined Rheumatology Practice (CRP)
    Kogarah, New South Wales 2217, Australia
  • Rheumatology, The Queen Elizabeth Hospital
    Woodville South, South Australia 5011, Australia
  • Southern Clinical Research Pty Ltd
    Hobart, Tasmania 7000, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • St Vincents Hospital Melbourne
    Fitzroy, Victoria 3065, Australia
  • Zentrum für klinische Studien Dr. Ursula Hanusch GmbH
    Wien, 1060, Austria
  • AKH
    Wien, 1090, Austria
  • Rheuma-Zentrum Wien Oberlaa
    Wien, 1100, Austria
  • Reumaclinic
    Genk, 3600, Belgium
  • Universitair Ziekenhuis Gent
    Gent, 9000, Belgium
  • Saint Joseph Hospital
    Gilly, 6060, Belgium
  • Universitaire Ziekenhuizen Leuven - Campus Gasthuisberg
    Leuven, 3000, Belgium
  • Hopital Ambroise Pare
    Mons, 7000, Belgium
  • The Waterside Clinic
    Barrie, Ontario L4M 6L2, Canada
  • SKiN Center for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • Centre de Recherche Musculo-Squelettique
    Trois-Rivieres, Quebec G8Z 1Y2, Canada
  • Polmed Research Inc.
    Saskatoon, Saskatchewan S7K 0H6, Canada
  • Group de recherche en maladies osseuses
    Quebec, G1V 3M7, Canada
  • Frederiksberg Hospital
    Frederiksberg, Hovedstaden 2000, Denmark
  • Aalborg Universitetshospital - Psykiatrien
    Aalborg, 9000, Denmark
  • Helsinki University Hospital, HYKS
    Helsinki, 00029, Finland
  • Kiljava Medical Research
    Hyvinkaa, 05800, Finland
  • Terveystalo Kouvola
    Kouvola, 45100, Finland
  • Turun Yliopistollinen Keskussairaala
    Turku, 20521, Finland
  • Hôpital Trousseau, CHRU de Tours
    Chambray-lès-Tours, 37170, France
  • Centre Hospitalier de Vendee Les Oudairies
    La Roche Sur Yon, 85025, France
  • Hopital Edouard Herriot
    Lyon Cedex 03, 69003, France
  • Centre hospitalier universitaire Lapeyronie
    Montpellier Cedex 5, 34295, France
  • Nouvel Hôpital Orléans La Source
    Orleans CEDEX 2, 45067, France
  • Hôpital Pierre-Paul Riquet
    Toulouse cedex 9, 31059, France
  • Klinikum der Universität München
    München, Bayern 80336, Germany
  • Klinikum der Johann Wolfgang Goethe-Universität Frankfurt
    Frankfurt am Main, Hessen 60590, Germany
  • Rheumazentrum Ratingen
    Ratingen, Nordrhein-Westfalen 40878, Germany
  • HRF Hamburger Rheuma Forschungszentrum
    Hamburg, 20095, Germany
  • Allergo-Derm Bakos Kft
    Szolnok, Jasz-Nagykun-Szolnok 5000, Hungary
  • Obudai Egeszsegugyi Centrum Kft
    Budapest, 1036, Hungary
  • UNO Medical Trials Kft.
    Budapest, 1135, Hungary
  • Vital Medical Center
    Veszprem, 8200, Hungary
  • Care Hospital
    Hyderabad, Andhra Pradesh 500035, India
  • King George Hospital
    Visakhapatnam, Andhra Pradesh 530002, India
  • Sir Ganga Ram Hospital
    New Delhi, Delhi 110060, India
  • Panchshil Hospital
    Ahmedabad, Gujarat 380005, India
  • Byramjee Jeejeebhoy Medical College & Civil Hospital
    Ahmedabad, Gujarat 380016, India
  • Shalby Hospital
    Ahmedabad, Gujarat 532004, India
  • Government Medical College & Sir Sayajirao General Hospital
    Vadodara, Gujarat 390001, India
  • Artemis Hospital
    Gurgaon, Haryana 122001, India
  • Narayana Hrudayalaya Hospital
    Bangalore, Karnataka 560099, India
  • Kokilaben Dhirubhai Ambani Hospital &Medical Research Inst.
    Mumbai, Maharashtra 400053, India
  • Ruby Hall Clinic and Grant Medical Foundation
    Pune, Maharashtra 411001, India
  • Krishna Institute of Medical Sciences Ltd.
    Secunderabad, Telengana 500003, India
  • Apollo Gleneagles Hospitals
    Kolkata, West Bengal 700054, India
  • Barzilai Medical Center
    Ashkelon, 78278, Israel
  • Rambam Medical Center
    Haifa, 3109601, Israel
  • Carmel Medical Center
    Haifa, 3436212, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Rabin Medical Center
    Petach Tikva, 4941492, Israel
  • Sheba Medical Center
    Ramat Gan, 5266202, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Assaf Harofeh Medical Center
    Zerifin, 6093000, Israel
  • Istituto Clinico Humanitas
    Rozzano, Milano 20089, Italy
  • Istituto Ortopedico Rizzoli
    Bologna, 40136, Italy
  • Presidio Ospedaliero Vittorio Emanuele
    Catania, 95124, Italy
  • Fondazione Universitaria degli Studi G D'Annunzio
    Chieti, 66100, Italy
  • Policlinico di Tor Vergata
    Roma, 00133, Italy
  • Complesso Integrato Columbus
    Roma, 00168, Italy
  • Ospedale Policlinico Giambattista Rossi, Borgo Roma
    Verona, 37134, Italy
  • Centro Medico del Angel S.C.
    Mexicali, Baja California 21100, Mexico
  • Ctro Inv en Artritis y Osteoporosis SC
    Mexicali, Baja California 21200, Mexico
  • CIMAB S.A. de C.V.
    Torreon, Coahuila 27000, Mexico
  • Grupo Médico CAMINO S.C.
    México City, Distrito Federal 03310, Mexico
  • Clínica Enfermedades Crónicas y Procedimientos Especiales SC
    Morelia, Michoacan 58249, Mexico
  • Centro Investigacion de Tratam Innovadores de Sinaloa SC
    Culiacan, Sinaloa 80000, Mexico
  • Cemdeicy S.C.P.
    Merida, Yucatán 97130, Mexico
  • RM Pharma Specialists S.A. de C.V.
    Distrito Federal, 3100, Mexico
  • Antonius Ziekenhuis
    Sneek, 8601 ZK, Netherlands
  • NZOZ Centrum Reumatologiczne Ind. Prak.
    Elblag, 82-300, Poland
  • "Dermed" Centrum Medyczne Sp. z o.o.
    Lodz, 90-265, Poland
  • Twoja Przychodnia-Centrum Medyczne Nowa Sol
    Nowa Sol, 67100, Poland
  • Rheuma Medicus Zakład Opieki Zdrowotnej
    Warsaw, 02-118, Poland
  • DermMEDICA Sp. z o.o.
    Wroclaw, 51-318, Poland
  • Greenacres Hospital
    Port Elizabeth, Eastern Cape 6045, South Africa
  • Clinresco Centres (Pt) Ltd
    Johannesburg, Gauteng 1619, South Africa
  • Suite 509 Umhlanga Netcare Medical Centre
    Durban, KwaZulu-Natal 4319, South Africa
  • Arthritis Clinical Research Trial Unit
    Pinelands, Western Cape 7405, South Africa
  • Winelands Medical Research Centre
    Stellenbosch, Western Cape 7600, South Africa
  • St Augustines Hospital
    Durban, 4001, South Africa
  • Emmed Research
    Muckleneuk, 0135, South Africa
  • Prof Ally
    Pretoria, 0002, South Africa

Showing the first 100 of 131 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Deodhar AA, Combe B, Accioly AP, Bolce R, Zhu D, Gellett AM, Sprabery AT, Burmester GR. Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient-years of exposure. Ann Rheum Dis. 2022 Jul;81(7):944-950. doi: 10.1136/annrheumdis-2021-222027. Epub 2022 Apr 7. PubMed 35393269 ↗
  • Elewski BE, Blauvelt A, Gallo G, Wolf E, McKean-Matthews M, Burge R, Merola JF, Gottlieb AB, Guenther LC. Simultaneous Nail and Skin Clearance in Ixekizumab Head-to-Head Trials for Moderate-to-Severe Psoriasis and Psoriatic Arthritis. Dermatol Ther (Heidelb). 2022 Apr;12(4):911-920. doi: 10.1007/s13555-022-00704-2. Epub 2022 Mar 13. PubMed 35279805 ↗
  • Smolen JS, Sebba A, Ruderman EM, Schulze-Koops H, Sapin C, Gellett AM, Sprabery AT, Li L, de la Torre I, Gallo G, Liu-Leage S, Pillai S, Reis P, Nash P. Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naive Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study. Rheumatol Ther. 2020 Dec;7(4):1021-1035. doi: 10.1007/s40744-020-00250-3. Epub 2020 Nov 16. PubMed 33200394 ↗
  • Smolen JS, Mease P, Tahir H, Schulze-Koops H, de la Torre I, Li L, Hojnik M, Sapin C, Okada M, Caporali R, Gratacos J, Goupille P, Liu Leage S, Pillai S, Nash P. Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naive to biological disease-modifying antirheumatic drug: final results by week 52. Ann Rheum Dis. 2020 Oct;79(10):1310-1319. doi: 10.1136/annrheumdis-2020-217372. Epub 2020 Jul 13. PubMed 32660977 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Nov 2018, 14 months.

Results were first posted in Apr 2019, 4 months after primary completion.

Of 33 phase 4 interventional studies under Arthritis, Psoriatic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 37. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2017
First posted
May 12, 2017
StartActual
Aug 24, 2017
Primary completionActual
Nov 15, 2018
CompletionActual
Sep 4, 2019
Results first posted
Apr 2, 2019
Last update
Nov 3, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03151551
Responsible party
Sponsor
First posted
May 12, 2017
Start date
Aug 24, 2017
Primary completion
Nov 15, 2018
Completion
Sep 4, 2019
Results posted
Apr 2, 2019
Last update
Nov 3, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion